E. Ohman J or Asset Management AB Purchases 2,150 Shares of Zoetis Inc. (NYSE:ZTS)

E. Ohman J or Asset Management AB boosted its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 11.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,750 shares of the company's stock after purchasing an additional 2,150 shares during the period. E. Ohman J or Asset Management AB's holdings in Zoetis were worth $3,381,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC bought a new position in Zoetis during the 3rd quarter worth about $31,000. First Personal Financial Services bought a new position in Zoetis during the 3rd quarter worth about $33,000. Capital Performance Advisors LLP bought a new position in Zoetis during the 3rd quarter worth about $33,000. Dunhill Financial LLC increased its holdings in Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock worth $33,000 after purchasing an additional 75 shares in the last quarter. Finally, Quarry LP increased its holdings in Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company's stock worth $36,000 after purchasing an additional 153 shares in the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Stock Performance

NYSE:ZTS traded up $0.30 during mid-day trading on Tuesday, hitting $172.24. The stock had a trading volume of 2,696,175 shares, compared to its average volume of 2,685,644. The company's 50 day simple moving average is $169.48 and its 200 day simple moving average is $179.39. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The stock has a market cap of $77.71 billion, a price-to-earnings ratio of 32.38, a PEG ratio of 2.72 and a beta of 0.90. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business's revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period last year, the business posted $1.36 earnings per share. On average, equities research analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be given a dividend of $0.50 per share. The ex-dividend date is Tuesday, January 21st. This is an increase from Zoetis's previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a yield of 1.16%. Zoetis's dividend payout ratio (DPR) is 37.59%.

Analyst Ratings Changes

ZTS has been the subject of several analyst reports. Leerink Partners initiated coverage on Zoetis in a report on Monday, December 2nd. They issued an "outperform" rating and a $215.00 price objective for the company. Stifel Nicolaus decreased their price objective on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. UBS Group initiated coverage on Zoetis in a report on Monday, December 9th. They issued a "neutral" rating and a $196.00 price objective for the company. Morgan Stanley decreased their price objective on Zoetis from $248.00 to $243.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. Finally, JPMorgan Chase & Co. raised their price objective on Zoetis from $225.00 to $230.00 and gave the company an "overweight" rating in a report on Friday, October 11th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Zoetis has an average rating of "Buy" and a consensus target price of $215.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.